Bailard, Inc. Blueprint Medicines Corp Transaction History

Bailard, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 27, 2022	SELL	$45.23 - $70.15 $2.06 Million - $3.2 Million	-45,577 Reduced 55.96%	35,867 $1.81 Million
Q1 2022 Apr 25, 2022	SELL	$54.1 - $110.08 $891,135 - $1.81 Million	-16,472 Reduced 16.82%	81,444 $5.2 Million
Q4 2021 Feb 10, 2022	SELL	$94.25 - $115.99 $96,417 - $118,657	-1,023 Reduced 1.03%	97,916 $10.5 Million
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $1.16 Million - $1.56 Million	14,294 Added 16.89%	98,939 $10.2 Million
Q2 2021 Aug 13, 2021	BUY	$82.78 - $101.0 $6.43 Million - $7.84 Million	77,645 Added 1109.21%	84,645 $7.45 Million
Q1 2021 May 13, 2021	BUY	$90.71 - $108.28 $634,970 - $757,960	7,000 New	7,000 $681,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.